

SIGNET Update
CTAG October 2024

The SIGNET trial, randomising adult brain-dead donors to receive either Simvastatin 80mg or standard treatment is now in its 4th year. We have recruited almost 1300 donors. With the continued reduction in DBD donors since Covid, we are behind our final target of 2600 donors and are planning to apply to NHRI for an extension.

However, it remains the biggest donor intervention study in the world, taking advantage of the unique circumstances of donation, retrieval and transplant data collection in the UK.

Clinical outcomes in the heart, as collected in the Transplant Registry, are the Primary Outcome, hence the importance of CTAG-Heart to this study. We are grateful for your continuing support

There remain no safety concerns, with no serious adverse events. A mechanistic study, using QUOD samples from the same donors, will produce results later this year.

If you know of other studies, either in the donor or recipient, which might affect early outcome, please get in touch with us. We have a range of co-enrollment arrangements so that neither study is compromised

Finally, John Dark and Dan Harvey, the co-chief investigators, would be very interested to hear of any suggestions for SIGNET 2, a future study exploiting the framework we have assembled for SIGNET

John Dark

j.h.dark@ncl.ac.uk

<https://www.nhsbt.nhs.uk/clinical-trials-unit/current-trials-and-studies/signet/>